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Background: Alstrӧm syndrome and Bardet-Biedl syndrome are autosomal recessively inherited ciliopathies with common 
characteristics of obesity, diabetes, and blindness. Alstrӧm syndrome is caused by a mutation in the ALMS1 gene, and Bardet-
Biedl syndrome is caused by mutations in BBS1-16 genes. Herein we report genetically confirmed cases of Alstrӧm syndrome 
and Bardet-Biedl syndrome in Korea using whole exome sequencing. 
Methods: Exome capture was done using SureSelect Human All Exon Kit V4+UTRs (Agilent Technologies). HiSeq2000 system 
(Illumina) was used for massive parallel sequencing. Sanger sequencing was used for genotype confirmation and familial coseg-
regation analysis. 
Results: A 21-year old Korean woman was clinically diagnosed with Alstrӧm syndrome. She had diabetes, blindness, obesity, se-
vere insulin resistance, and hearing loss. Whole exome sequencing revealed a nonsense mutation in exon 10 of ALMS1 
(c.8776C>T, p.R2926X) and a seven base-pair deletion resulting in frameshift mutation in exon 8 (c.6410_6416del, 
p.2137_2139del). A 24-year-old Korean man had Bardet-Biedl syndrome with diabetes, blindness, obesity, and a history of poly-
dactyly. Whole exome sequencing revealed a nonsynonymous mutation in exon 11 of the BBS1 gene (c.1061A>G, p.E354G) and 
mutation at the normal splicing recognition site of exon 7 of the BBS1 gene (c.519-1G>T). 
Conclusion: We found novel compound heterozygous mutations of Alstrӧm syndrome and Bardet-Biedl syndrome using whole 
exome sequencing. The whole exome sequencing successfully identified novel genetic variants of ciliopathy-associated diabetes.
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INTRODUCTION
Genetic mutations in ciliary proteins result in intracellular and 
intercellular signaling defects and consequently lead to multi-
organ developmental disorders [1]. Ciliopathies share clinical 
features such as mental retardation, cystic kidney disease, reti-
nal defects, polydactyly, obesity, and diabetes [2]. Alstrӧm syn-
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multiorgan systems and share common clinical features of 
blindness due to retinal defect, early onset obesity and diabetes 
[3,4]. Both syndromes are diagnosed based on clinical findings 
and are confirmed by genetic testing [5,6]. Until recently, both 
syndromes were confirmed with Sanger sequencing in experi-
enced laboratories [7,8]. However, it is now possible to deter-
mine the whole exome sequence variation using a next genera-
tion massive parallel sequencing technique [9]. In this study, 
we describe Korean patients with Alstrӧm syndrome and Bar-
det-Biedl syndrome who were genetically confirmed using 
whole exome sequencing and provide information that might 
lead to possible translational implications.
METHODS
After acquiring written informed consent from patients and 
family members, we sequenced whole exomes of peripheral 
blood DNA from affected probands. The SureSelect Human 
All Exon Kit V4+UTRs (Agilent Technologies, Santa Clara, 
CA, USA) was used for whole exome capture and HiSeq 2000 
Sequencing System (Illumina Inc., San Diego, CA, USA) was 
used for massive parallel sequencing. The sequence reads were 
mapped against human genome 19 using Burrows-Wheeler 
Alignment software [10]. Sequence variation including single 
nucleotide polymorphisms and insertion/deletions were de-
tected by The Genome Analysis Toolkit (GATK; Broad Insti-
tute, Cambridge, MA, USA) software [11]. Sanger sequencing 
was performed on DNA from the probands for genotype con-
firmation and the family members for familial cosegregation 
analysis.
RESULTS
Case 1: Alstrӧm syndrome
A 21-year-old Korean woman had diabetes since age 13, poorly 
controlled glucose level with obesity (body mass index [BMI], 
27.9 kg/m2), severe insulin resistance (total daily requirement 
of insulin, 190 IU/day; homeostatic model assessment for insu-
lin resistance [HOMA-IR] index, 62.8; HOMA-β, 113.7), and 
acanthosis nigricans. She had nystagmus and photophobia 
when she was 1 year old, which led to childhood blindness. She 
also presented with mild sensorineural hearing loss, nonalco-
holic steatohepatitis, renal dysfunction, and hypertension. Ad-
ditionally, she had secondary amenorrhea caused by polycystic 
ovary syndrome since age 12. Her cardiac function was normal 
and did not have cognitive dysfunction or general intelligence 
impairment during her developmental period.
 Whole exome sequencing revealed the patient to have a com-
pound heterozygous mutation in the ALMS1 gene. The first 
mutation was a seven base pair deletion resulting in a frame 
shift that introduced a new stop codon at chr2: 73,680,067 (Na-
tional Center for Biotechnology Information build, NCBI build 
37) in exon 8 of the ALMS1 gene (c.6410_6416del, p.2137_ 
2139del). The second mutation was a stop codon in exon 10 of 
the ALMS1 gene (c.8776C>T, p.R2926X) at chr2: 73,717,865 
(NCBI build 37). As there was no consanguineous relationship, 
other family members did not showed features of Alstrӧm syn-
drome. We confirmed these mutations by Sanger sequencing 
and found that the c.8776C>T mutation was maternally inher-
ited (Fig. 1A). The seven base pair deletion might have been ei-
ther inherited from the patient’s father or newly introduced as a 
de novo mutation. Her father passed away several years ago, and 
we were not able to obtain his DNA.
Case 2: Bardet-Beidl syndrome
A 24-year-old Korean man was diagnosed with diabetes at age 
19. He had polyphagia with severe obesity (BMI, 40.4 kg/m2). 
His blood glucose level was well-controlled with glucagon-like 
peptide-1 (GLP-1) agonist combined with oral antihyperglyce-
mic agent. With a GLP-1 agonist, his glycosylated hemoglobin 
decreased from 11.8% to 6.9% within 8 months. He had retini-
tis pigmentosa resulting in blindness since age 10. He had poly-
dactyly of both hands and a personality disorder. We clinically 
diagnosed Bardet-Biedl syndrome. We investigated variants in 
BBS1 to BBS16, using whole exome sequencing. There were no 
homozygous autosomal recessive variants in these genes. 
Whole exome sequencing revealed a mutation at the normal 
splicing recognition site of exon 7 of the BBS1 gene (c.519-
1G>T) at chr11: 66,283,331 (NCBI build 37). The splice site 
score for this variant was –6.4, which implies that it is function-
ally detrimental (http://www.fruitfly.org/seq_tools/splice.html) 
[4]. A second mutation was a novel nonsynonymous mutation 
in exon 11 of the BBS1 gene (c.1061A>G, p.E354G) at chr11: 
66,291,304 (NCBI build 37). The PolyPhen-2 score of the vari-
ant was 0.99 and predicted to be probably damaging (http://ge-
netics.bwh.harvard.edu/pph/) [12,13]. Consanguineous mat-
ing was not involved in the patient’s family. No family member 
had the typical phenotype of Bardet-Biedl syndrome. Sanger 
sequencing revealed that the splice site variant, c.519-1G>T, 
was maternally inherited and the nonsynonymous mutation, 
Two cases of ciliopathy-associated diabetes
441Diabetes Metab J 2015;39:439-443http://e-dmj.org
c.1061A>G, was paternally inherited (Fig. 1B). In other words, 
the patient had a compound heterozygous mutation in BBS1.
 
DISCUSSION
Alstrӧm syndrome (OMIM 203800) is a rare autosomal reces-
sive ciliopathy caused by ALMS1 gene mutation. The preva-
lence of Alstrӧm syndrome is less than 1:1,000,000. The key fea-
tures are childhood obesity, early-onset diabetes (70% by age 
20), blindness from congenital retinal dystrophy, and sensori-
neural hearing loss [3]. It is reported that exons 8, 10, and 16 of 
the ALMS1 gene are mutational hot spots. Patients with muta-
tions in exon 8 seem to have less renal involvement than those 
with exon 16 mutations [14]. In this paper, we identified a com-
pound heterozygous mutation in exon 8 and 10 of the ALMS1 
gene, the patient also showed mild to moderate renal insuffi-
ciency. Before the advent of the whole exome sequencing tech-
nology, Sanger sequencing was used for genetic diagnosis of 
Alstrӧm syndrome [5]. As the ALMS1 gene consists of 23 exons 
and the size of the transcript is 12,922 base-pairs, it would re-
quire a large number of polymerase chain reaction (PCR) prim-
ers. In addition, we could not exclude the possibility of pheno-
copy or locus heterogeneity. Therefore, we opted for whole 
exome sequencing rather than Sanger sequencing. We used 
Sanger sequencing for both genotype validation and segrega-
tion analysis and confirmed the causality of the genetic variant. 
In previous reports, only one case of Alstrӧm syndrome has 
been reported in a Korean but without genetic confirmation 
[15]. This is the first genetically confirmed case of Alstrӧm syn-
drome using whole exome sequencing.
 Bardet-Biedl syndrome (OMIM 209900) is also a rare auto-
somal recessive ciliopathy caused by at least 16 genes, including 
BBS1 to BBS16. The estimated prevalence is 1:160,000 in north-
ern European populations. Bardet-Biedl syndrome is charac-
terized by retinal dystrophy (>90%), diabetes (<25%), truncal 
obesity (72%), post-axial polydactyly, cognitive impairment, 
male hypogonadotrophic hypogonadism, and renal abnormali-
ties [4]. Bardet-Biedl syndrome is differentiated from Altsrӧm 
syndrome by the presence of polydactyly, cognitive impair-
ment, less severe hearing loss and delayed onset type 2 diabetes 
mellitus [3,4]. Genotype-phenotype correlations are poor, even 
though one study suggests a milder phenotype-associated with 
the common mutation found in BBS1 [16]. In this paper, the 
subject had a compound heterozygous mutation in the BBS1 
A B
Fig. 1. Pedigrees of Alstrӧm syndrome and Bardet-Biedl syndrome patients. (A) The Alstrӧm syndrome patient had compound 
heterozygous mutations in the ALMS1 gene. A mutation in exon 10 of the ALMS1 gene (c.8776C>T, p.R2926X), which intro-
duced a stop codon, was maternally inherited, and a seven base pair deletion in exon 8 of ALMS1 gene mutation (c.6410_ 
6416del, p.2137_2139del) might have been inherited from the patient’s father or newly introduced as a de novo mutation. (B) The 
Bardet-Biedl syndrome patient also had a compound heterozygous mutation. A mutation at a normal splicing recognition site of 
exon 7 on the BBS1 gene (c.519-1G>T) was maternally inherited, and a novel nonsynonymous mutation in exon 11 of BBS1 
gene (c.1061A>G, p.E354G) was paternally inherited. Circles, females; squares, males; filled symbols indicate affected members; 
empty symbols indicate healthy family members; symbols with dots in the center indicate obligate carriers; slashed symbols indi-
cate those who had previously died. The DNA sequence electropherograms are shown for the reference (top) and subject (bot-
tom). The sequences were analyzed using Variant Reporter v.1.1 (Applied Biosystems) with IUPAC (The International Union of 
Pure and Applied Chemistry) codes. WT, wild type.
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gene and had retinitis pigmentosa. Particularly, he had a good 
response to the GLP-1 agonist. Until recently, one case of Bar-
det-Biedl syndrome with BBS10 gene mutation was reported 
in Korea with genetic confirmation by Sanger sequencing 
methods [17].
 The mechanism of diabetes associated with ciliopathies is 
not fully understood. The most important mechanism of ciliary 
dysfunction associated diabetes is considered to be insulin re-
sistance. In both patients, there were distinct clinical character-
istics of insulin resistance with early onset obesity and hyper-
phagia. However, further studies are required to understand the 
detailed molecular mechanism of diabetes with ciliopathies. 
 Whole exome sequencing is an attractive alternative to 
Sanger sequencing as it does not require predesigned specific 
primer sets for PCR. In addition, the cost of whole exome se-
quencing is expected to decrease below that of the Sanger se-
quencing in cases where the gene to be sequenced is of a cer-
tain size or larger. Recently, the United States Food and Drug 
Administration approved using the next generation sequencer, 
Illumina’s MiSeqDx for clinical application and to be marketed 
[18]. The pitfall of whole exome sequencing is that it does not 
evenly cover the whole exome and some parts of the genome 
might be omitted from the analysis. There could be sequenc-
ing error that could result in either false positive and false neg-
ative findings. Our study highlights a successful case of con-
firming novel genetic variants in a rare recessive disorder. 
 In summary, we report two Korean cases of ciliopathy-asso-
ciated diabetes, Alstrӧm syndrome and Bardet-Biedl syndrome. 
We found novel compound heterozygous mutations of Alstrӧm 
syndrome and Bardet-Biedl syndrome using whole exome se-
quencing. Whole exome sequencing could be used for genetic 
diagnosis of ciliopathy-associated diabetes. Further translation-
al research would be helpful for understanding functional 
mechanism of these variants. 
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